Herencia starts drilling deeper at Guamanga copper-gold project
Herencia Resources (LON:HER) today kicked off a deep drilling programme on the Guamanga copper-gold project in northern Chile.
It will drill four or five holes to test potential porphyry targets. Herencia says around 1,500 metres will be drilled in total. The first assay results from the programme are expected in April.
Yesterday Herencia revealed results from four of eleven shallow holes from Guamanga, which were drilled to depths between 60 and 122 metres. Three of the holes intersected copper-gold mineralisation.
"It is pleasing to see this drilling program commencing on time at Guamanga, following on from the recent positive results from the first four shallow drill holes," said managing director Michael Bohm.
"The confirmation of copper-gold mineralisation in the shallow drill holes, together with the surface geological indicators and the geophysical targets is a positive suite of results for the Guamanga JV partners.
"This is a busy period for our team with a high volume of assay data pending in the coming months."
Bohm added: "We look forward to receiving the assay results from the remaining seven shallow holes at Guamanga this month, the results from the current deep drilling program at Guamanga in April, and the on-going Patricia assay results over the coming two months.
Herencia is earning into a 51 per cent stake in the Guamanga project. The work on the follow-up drill programme at Guamanga will see Herencia fulfil its year-1 earn-in milestones under the joint venture agreement, the company said.
Related news
- Yellow Diamonds - A Gap in the Diamond market
- Coffee with Samso: Episode 1, Australian Tungsten Projects and How the Chinese Market View The Tungsten sector
- Chasing for Kryptonite, the unknown other Lithium source
- What is In-Situ Recovery? Mining in a National Park with no environmental footprint
- Buds & Duds: Cannabis stocks drop but Weekend Unlimited shares jump on CBD hemp seed news
- Hemispherx treats first patient with cancer drug Ampligen in Phase 2 clinical trials
- THC Global granted cannabis Manufacture Licence, shares surge 20%
.jpg)